Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program

Design Therapeutics, Inc. (DSGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patien

FORWARD AIR CORP (FWRD) filed an SEC Form 8-K — Other Events. Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship 2026 to 2028 Forecasted Annual Revenue from Customer Expected to Exceed 2025 Revenue Driven by Growth in Retained Services DALLAS – October 28, 2026 – F

Geron (GERN) halted its Phase 3 IMpactMF trial for imetelstat in myelofibrosis patients after an independent committee advised it was unlikely to meet the primary survival endpoint. The company plans to analyze the data and share findings later. Geron remains focused on its approved drug RYTELO and expanding its hematology business.

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

Kratos Defense & Security Solutions (KTOS) won a $33.6M contract from NASA to design and build a power system for the Space Reactor-1 Freedom spacecraft, launching in 2028. Kratos will work as a subcontractor to Sierra Lobo under NASA’s SpaceDOC III contract, providing a power conversion system for the mission to Mars. The spacecraft aims to demonstrate nuclear electric propulsion technology. According to the company, the contract is a significant milestone in advancing space nuclear propulsion.

Enlivex Ltd. (ENLV) has enrolled 135 patients in its Phase 2b trial for knee osteoarthritis, with topline data expected by mid-2027. The trial evaluates Allocetra's efficacy and safety in 182 patients across the U.S., Denmark, and Poland. The FDA granted RMAT designation to the therapy in July 2026.